Javascript was detected to be disabled. Javascript is required for some functions on this website.

Discussion Papers

The Heidelberg Health Economic Summer Schools 2006 – 2023: History, International Evaluation & Outlook

R. Schaefer, M. Schlander (2023):
The Heidelberg Health Economics Summer [& Winter] Schools 2006-2023: History, International Evaluation (2023) & Outlook.

InnoValHC Discussion Paper No. 36 / 2023
(ISBN 978 3 941609 34 1)

[View Paper …]

Swiss Social Preferences – Briefing Document: Essential Insights from the SoPHI Study

M. Schlander, H. Telser, B. Fischer, T. von Rechenberg, D. Hernandez, R. Schaefer – on behalf of the ESPM Project Group (2021):
The Swiss Social Preferences for Health Care Interventions (“SoPHI”) Study – Briefing on Essential Study Insights & Policy Implications.

InnoValHC Discussion Paper No. 35 / 2021
(ISBN 978 3 941609 33 4)

[View Paper …]

Economic Valuation of Life: The Value of a Statistical Life Year (VSLY) in Europe

M. Schlander, R. Schaefer, O. Schwarz (2017):
The Economic Value of a Statistical Life Year in Europe: Report of a Systematic Review [German].

InnoValHC Discussion Paper No. 34 / 2017
(ISBN 978 3 941609 32 7)

[View Paper …]

Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review 2016: An International Perspective

M. Schlander (2016):
Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review 2016: An International Perspective [Expert Statement].

InnoValHC Discussion Paper No. 33 / 2016

[Paper available on request ...]

Budgetary Impact and Cost Drivers of Drugs for Ultra-Rare Diseases (URDs) in Europe

M. Schlander, K. Stenner, A. Gandjour (2015):
Budgetary Impact and Cost Drivers of Drugs for Ultra-Rare Diseases (URDs) in Europe.

InnoValHC Discussion Paper No. 32 / 2015
(ISBN 978 3 941609 31 0)

[View Paper …]

Towards Social Cost Value Analysis: The Need for New Approaches for Evaluating Drugs for Ultra-Rare Diseases (URDs)

M. Schlander, S. Holm, E. Nord, J. Richardson, S. Garattini, P. Kolominsky-Rabas, D. Marshall, U. Persson, M. Postma, S. Simoens, O. de Solà Morales, K. Tolley, M. Toumi (2015):
Towards Social Cost Value Analysis: The Need for New Approaches for Evaluating Drugs for Ultra-Rare Diseases (URDs).

InnoValHC Discussion Paper No. 31 / 2015
(ISBN 978 3 941609 30 3)

[View Paper …]

Budget Impact of Drugs for Ultra-Rare Non-Oncological Diseases Projected to Remain Moderate in Europe

M. Schlander, C. Adarkwah, A. Gandjour (2014):
Budget Impact of Drugs for Ultra-Rare Non-Oncological Diseases Projected to Remain Moderate in Europe.

InnoValHC Discussion Paper No. 30 / 2014
(ISBN 978 3 941609 29 7)

[View Paper …]

The Institute´s Discussion Paper Series

M. Schlander in cooperation with R. Schaefer (2024):
The InnoValHC Discussion Paper Series (2005-2023): Discussion / Technical / Working Paper [Shortlist].

InnoValHC Discussion Paper Series
(2005-2023)

[View Shortlist …]

Attention-Deficit Hyperactivity Disorder (ADHD) in Nordbaden / Germany

M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer (2005):
Attention-Deficit Hyperactivity Disorder (ADHD) in Nordbaden / Germany: Administrative Prevalence & Implications for Health Care Provision and Future Research.

InnoValHC Discussion Paper No. 00 / 2005

[View Paper …]